MHC + X pp 66-71 | Cite as

Sendai Virus Infection of Tumor Cells Increases the Production of Autoreactive H-2 Specific Antibodies in Syngeneic Recipients

  • Adam Opolski
  • Laurent Degos
  • Marika Pla
Conference paper


The major histocompatibility complex (MHC) phenotype of neoplastic cells reflects both the cells tumorigenic history and its internal state of differentiation and metabolic activity. In many cases MHC expression probably also affects the outcome of the disease. An increasing body of evidence indicates that various agents are able to increase the immunogenicity of malignant cells. An increase in the immunogenicity of tumor cells was observed following in vitro treatment with various drugs (Koyama and Ishii 1969; Tsukagoshi and Hashimoto 1973; Frost et al. 1983; Carlow et al. 1985; Gorelik et al. 1985; Flood et al. 1987), UV light treatment (Peppoloni et al. 1985), and virus infection (Wakamiya et al. 1986; Williams et al. 1986) of tumor cells. Recently, we have shown (Opolski et al. 1987) that the median survival time of mice inoculated with Sendai virus-infected EL4 tumor cells was significantly longer (in some animals a complete rejection was observed) than in those inoculated with untreated EL4 cells. Moreover, most of the mice which rejected Sendai virus-infected EL4 cells were found to be resistant to subsequent inoculation of untreated EL4 tumor cells (Opolski et al. 1987). What remains unknown is which of the changes on the cell surface are responsible for the conversion of the weakly or nonimmunogenic tumor cells into a highly immunogenic form. Numerous experimental data indicate that cell surface antigens are recognized by T-Iymphocytes in association with MHC products (Zinkernagel and Doherty 1975). One might postulate that conversion of nonimmunogenic tumor cells into a highly imunogenic form would be paralleled by changes in expression of MHC products on the surface of tumor cells (Goodenow et al. 1985).


Major Histocompatibility Complex Sendai Virus Lewis Lung Carcinoma Tumor Syngeneic Recipient Sendai Virus Infection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abramson-Leeman SR, Cantor H (1983) Specificity of T cell clones for antigen and autologous major histocompatibility complex products determines specificity for foreign major histocompatibility complex products. J Exp Med 158: 428–437CrossRefGoogle Scholar
  2. Ashwell JD, Chen C, Schwartz RH (1986) High frequency and nonrandom distribution of alloreactivity in T cell clones selected for recognition of foreign antigen in association with self class II molecules. J Immunol 136: 389–395PubMedGoogle Scholar
  3. Askonas BA, Lin YL (1982) An influenza specific T-killer clone is restricted to H-2 Ld and cross-reacts with Dk region. Immunogenetics 16: 83–87PubMedCrossRefGoogle Scholar
  4. Braciale TJ, Andrew ME, Braciale VL (1981) Heterogeneity and specificity of cloned lines of influenza-virus-specific cytotoxic T lymphocytes. J Exp Med 153: 910–923PubMedCrossRefGoogle Scholar
  5. Čapková J, Hašek M, Kousalová M, Holáň V, Boubelík M (1983) Alloreactive cytotoxic anti-H-2 antibodies in sera of the syngeneically immunized C57BL/10ScSnPh, BALB/cJPh, and B10. A/SnPh mice. Folia Biol (Praha) 29: 200–212Google Scholar
  6. Carlow D, Kerbel R, Feltis T, Elliott B (1985) Enhanced expression of class I major histocompatibility complex gene (Dk) products on immunogenic variants of a spontaneous murine carcinoma. JNCI 75: 291–302PubMedGoogle Scholar
  7. Finberg R, Burakoff SJ, Cantor H, Benacerraf B (1978) Biological significance of alloreactivity: T cells stimulated by Sendai virus-coated syngeneic cells specifically lyse allogeneic target cells. Proc Natl Acad Sci USA 75: 5145–5149PubMedCrossRefGoogle Scholar
  8. Flood PM, Schreiber H, Ron Y (1987) Protective immunity to progressive tumors can be induced by antigen presented on regressor tumors. J Immunol 138: 3573–3579PubMedGoogle Scholar
  9. Frelinger JA, Niederhuber JE, David CS, Shreffler DC (1974) Evidence for the expression of la (H-2-associated) antigens on thymus derived lymphocytes. J Exp Med 140: 1273–1284PubMedCrossRefGoogle Scholar
  10. Froscher BG, Klinman NR (1986) Immunization with SV40-transformed cells yields mainly MHC-restricted monoclonal antibodies. J Exp Med 164: 196–210PubMedCrossRefGoogle Scholar
  11. Frost P, Kerbel R, Bauer E, Tartamella-Biondo R, Cefalu W (1983) Mutagen treatment as a means for selecting immunogenic variants from otherwise poorly immunogenic malignant murine tumors. Cancer Res 43: 125–132PubMedGoogle Scholar
  12. Goodenow RS, Vogel JM, Linsk RL (1985) Histocompatibility antigens on murine tumors. Science 230: 777–783PubMedCrossRefGoogle Scholar
  13. Gorelik E, Peppoloni S, Overton R, Herberman RB (1985) Increase in H-2 antigen expression and immunogenicity of BL6 melanoma cells treated with N-methyl-nitronitrosoguanine. Cancer Res 45: 5341–5347PubMedGoogle Scholar
  14. Ivanyi P, van Mourik P, Breuning M, Melief CJM (1980) Anti-H-2 antibodies induced by syngeneic immunization. Immunogenetics 10: 319–332CrossRefGoogle Scholar
  15. Kievits F, Rocca A, Opolski A, Limpens J, Leupers T, Kloosterman T, Boerenkamp WJ, Pla M, Ivanyi P (1987a) Induction of H-2-specific antibodies by injections of syngeneic Sendai virus-coated cells. Eur J Immunol 17: 27–35PubMedCrossRefGoogle Scholar
  16. Kievits F, Opolski A, Boerenkamp WJ, Pla M, Ivanyi P (1987b) Monoclonal H-2 class I specific antibodies isolated after immunization of C57BL/6 mice with syngeneic Sendai virus-coated cells. In: David CS (ed) H-2 antigens: genes, molecules, function. Plenum, New York, p 669–680Google Scholar
  17. Koyama K, Ishii K (1969) Induction of non-transplantable mutant clones from an ascites tumor. Gann 60: 367–374PubMedGoogle Scholar
  18. Mierau R, Cramer M (1984) Serological and immunochemical analysis of H-2 class I molecules encoded by the Db region. Immunogenetics 20: 341–345PubMedCrossRefGoogle Scholar
  19. Opolski A, Kievits F, Ivanyi P (1986) Polymorphic and autoreactive H-2-specific monoclonal antibody isolated after injections of syngeneic Sendai virus-coated lymphocytes. Immunogenetics 24: 402–408PubMedCrossRefGoogle Scholar
  20. Opolski A, Degos L, Pla M (1988) Rejection of Sendai virus-infected EL4 thymoma cells by mice. Cancer Immunol Immunother (submitted)Google Scholar
  21. Peppoloni S, Herberman RB, Gorelik E (1985) Induction of highly immunogenic variants of Lewis lung carcinoma tumor by ultraviolet irradiation. Cancer Res 45: 2560–2566PubMedGoogle Scholar
  22. Pestalozzi B, Stitz L, Zinkernagel RM (1987) Monoclonal antibodies against viral determinants are not restricted to the K/D end of the major histocompatibility complex. J Exp Med 166: 295–299PubMedCrossRefGoogle Scholar
  23. Philipps C, McMillan M, Flood PM, Murphy DB, Forman J, Lancki D, Womack JE, Goodenow RE, Schreiber H (1985) Identification of a unique tumor-specific antigen as a novel class I major histocompatibility molecule. Proc Natl Acad Sci USA 82: 5140–5144PubMedCrossRefGoogle Scholar
  24. Schmidt W (1987) H-2-specific antibodies induced by injection of syngeneic leukemia cells. Immunogenetics 25: 215–221PubMedCrossRefGoogle Scholar
  25. Schmidt W, Alonzo A (1983) Biologic significance of autoantibodies against H-2 antigens in syngeneic antitumor sera. Transplant Proc 15: 2118–2120PubMedGoogle Scholar
  26. Takahashi T, Matsudaira Y, Obata Y, Moriwaki K (1987) An autoreactive H-2-specific monoclonal antibody with allospecificity. Immunogenetics 26: 105–106PubMedCrossRefGoogle Scholar
  27. Tamminen WL, Wraith D, Barber DH (1987) Searching for MHC-restricted anti-viral antibodies: Antibodies recognizing the nucleoprotein of influenza virus dominate the serological response of C57BL/6 mice to syngeneic influenza-infected cells. Eur J Immunol 17: 999–1006PubMedCrossRefGoogle Scholar
  28. Tsukagoshi S, Hashimoto Y (1973) Increased immunosensitivity in nitrogen mustard-resistant Yoshida sarcoma. Cancer Res 33: 1038–1042PubMedGoogle Scholar
  29. Van Leeuven A, Goulmy E, van Rood JJ (1979) Major histocompatibility complex-restricted antibody reactivity mainly, but not exclusively, directed against cells from male donors. J Exp Med 150: 1075–1083CrossRefGoogle Scholar
  30. Wakamiya N, Wang Y-L, Imai H, Gu H-X, Ueda S, Kato S (1986) Feasibility of UV-inactivated vaccinia virus in the modification of tumor cells for augmentation of their immunogenicity. Cancer Immunol Immunother 23: 125–129PubMedCrossRefGoogle Scholar
  31. Williams ME, Cox DC, Stevenson JR (1986) Rejection of reovirus-treated L1210 leukemia cells by mice. Cancer Immunol Immunother 23: 87–92PubMedCrossRefGoogle Scholar
  32. Wylie DE, Sherman LA, Klinman NR (1982) Participation of the major histocompatibility complex in antibody recognition of viral antigens expressed on infected cells. J Exp Med 155: 403–414PubMedCrossRefGoogle Scholar
  33. Yang H, Welsh RM (1986) Induction of alloreactive cytotoxic T cells by acute virus infection of mice. J Immunol 136: 1186–1193PubMedGoogle Scholar
  34. Zinkernagel RM, Doherty PC (1975) H-2 compatibility requirement for T cell mediated lysis of target cells infected with lymphocytic choriomeningitis virus. Different cytotoxic T-cell specificities are associated with structures coded for in H-2K or H-2D. J Exp Med 141: 1427–1436PubMedCrossRefGoogle Scholar
  35. Zinkernagel RM, Doherty PC (1979) MHC-restricted cytotoxic T cells: studies on the biological role of polymorphic major transplantation antigens determining T cell restriction specificities, function, and responsiveness. Adv Immunol 27: 51–177PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • Adam Opolski
    • 1
  • Laurent Degos
    • 1
  • Marika Pla
    • 1
  1. 1.Laboratory of Mouse ImmunogeneticsU93 INSERM, Saint Louis HospitalParisFrance

Personalised recommendations